Insulin Regimen Adjustment for Poorly Controlled Type 2 Diabetes

Current Regimen Assessment

The American Diabetes Association recommends that patients with type 2 diabetes have basal insulin requirements typically higher, often approaching 0.3-0.5 units/kg/day, which is not met in the current regimen of 10 units of Lantus (long-acting insulin glargine) 3, 4
The patient's current insulin regimen shows a significant imbalance between basal and bolus insulin components, with inadequate basal insulin coverage, as evidenced by persistently elevated blood glucose levels in the 200-300 mg/dL range 1, 2, 3, 4

The American College of Endocrinology suggests increasing Lantus from 10 units to 20-25 units once daily, administered at the same time each evening, to establish adequate 24-hour basal insulin coverage 1, 4
The Endocrine Society recommends titrating Lantus by adding 2-4 units every 3-4 days until fasting blood glucose consistently reaches 100-130 mg/dL, with a strength of evidence rated as high 2, 3
The American Association of Clinical Endocrinologists advises distributing mealtime insulin across three meals based on carbohydrate content, with a typical distribution of 30-40% breakfast, 30-40% lunch, and 30-40% dinner 2, 3, 5

The American Diabetes Association recommends monitoring blood glucose before meals and at bedtime daily during the adjustment period to assess for patterns of hyperglycemia or hypoglycemia and guide further adjustments 1, 3
The European Association for the Study of Diabetes suggests that if fasting glucose is at target but post-meal glucose remains elevated, the focus should be on increasing mealtime insulin, with a strength of evidence rated as moderate 5

The International Diabetes Federation notes that the total daily insulin requirement for patients with type 2 diabetes is often around 1 unit/kg/day, with approximately 50% as basal insulin, which is not met in the current regimen 4
The American College of Cardiology recommends considering adding or optimizing oral agents such as metformin if not contraindicated, to improve glycemic control 1, 2

The Endocrine Society suggests that if blood glucose remains poorly controlled despite optimized basal-bolus insulin therapy, consideration should be given to adding a GLP-1 receptor agonist to improve postprandial control and potentially reduce insulin requirements, with a strength of evidence rated as high 2, 3